Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACCLAIM: Abatacept in Relapsing-Remitting MS
NCT01116427Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2010
- Primary completion
- Jun 2014
- Modality
- Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of abatacept in relapsing-remitting multiple sclerosis (RRMS) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Mean Number of New Inflammatory MRI Lesions Per Monthly Scans. Started Sep 2010; status: completed.
02
Drugs
abatacept
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT01116427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01116427.